CBD for Endometriosis - What Science Says 2026

Endometriosis affects about 10% of women and girls of reproductive age, approximately 190 million people worldwide, with an average time from first symptoms to diagnosis ranging from 4 to 12 years (WHO, 2025). During this long wait, many patients seek anything to get through the day. Hence the question about cannabidiol, asked today more often than ever, usually somewhere between one visit and another. This text does not answer it with a promise or denial. It shows exactly what has been measured, in which studies and on how many people, where evidence ends and hypothesis begins, what European cannabinoid guidelines do not say at all, and why the decision to use cannabidiol in diagnosed endometriosis is made by the managing physician, not a guidebook.

KEY INFORMATION
• Endometriosis affects about 10% of women of reproductive age, and WHO states directly that there is no cure (WHO, 2025).
• There is no randomized clinical trial of cannabidiol in endometriosis. The most cited work is a survey, not a controlled study.
• EFSA states that cannabidiol safety cannot be established in people taking medications, pregnant or breastfeeding women, and those under 25 years old.
• This text does not provide any doses. In diagnosed disease, dosing is determined by the managing physician.

What is endometriosis and who does it affect?

It is a chronic disease in which tissue similar to the uterine lining occurs outside its cavity, causing inflammation, pain, and scarring. According to the World Health Organization, it affects about 10% of women and girls of reproductive age, approximately 190 million people, and currently has no known cure (WHO, 2025).

The clinical picture varies widely. Some patients have few or no symptoms, while others experience pelvic pain severe enough to prevent work and study. Menstrual pain is often accompanied by pain outside menstruation, pain during intercourse, and bowel and bladder symptoms. For many women, difficulty conceiving is the first reason to see a doctor.

The 2022 guidelines of the European Society of Human Reproduction and Embryology describe this diversity as a fundamental challenge. The document contains 109 recommendations covering diagnosis, pain and infertility treatment, disease recurrence management, and special situations such as endometriosis in adolescents and postmenopausal women (Becker, Human Reproduction Open, 2022).

It is worth noting the cautious tone of this document. The authors write that based on existing evidence, no firm recommendations could be made regarding the best treatment choice, and for some issues, evidence is too limited to support any recommendation. This is a reference point for everything this text says further about cannabidiol.

Why does endometriosis diagnosis take so many years?

Because the leading symptom, painful menstruation, is often treated as normal, and imaging does not always show changes. The World Health Organization reports that the average time to diagnosis today ranges from 4 to 12 years. This span covers the patient’s entire youth, including career and family decisions made without knowledge of the disease.

An Australian 2020 survey gives this a concrete dimension. Of 409 responses, 340 were from people with diagnosed endometriosis, with an average diagnostic delay of eight years. The authors noted a clear decrease in both delay and number of doctors visited before diagnosis among those presenting in later years (Armour, Scientific Reports, 2020).

The same study compared disease impact on life in diagnosed and undiagnosed groups. Both reported moderate or severe menstrual and pelvic pain outside the cycle, and significant negative effects on social relationships, education, and intimate life. Diagnosis does not change symptom severity but opens the way to treatment.

For this article’s topic, this has one practical consequence. Self-supplementation before diagnosis may relieve the symptom that is the only signal prompting a visit. Prolonging an already long diagnostic journey is a real cost not visible at the decision moment.

Is laparoscopy still the gold standard for diagnosis?

Not to the extent most guides claim. The 2022 guidelines directly challenge laparoscopy and histopathology as reference diagnostic tests, shifting emphasis to clinical diagnosis and imaging (Becker, Human Reproduction Open, 2022). This is one of several changes expected to transform clinical practice.

The statement about laparoscopy as gold standard still circulates in endometriosis texts and is often referenced to these guidelines. The link leads to a document saying the opposite. This is a good example where verifying source existence and credibility does not resolve the issue.

The practical difference is significant for the patient. If diagnosis can be based on clinical and imaging findings, waiting for surgery is no longer a prerequisite for treatment. A negative imaging result does not exclude disease, so persistent symptoms warrant further diagnostics, not closure.

The guidelines also describe possible actions: pain treatment, pharmacotherapy, surgery, and for infertility, surgery or assisted reproduction techniques. Symptomatic support outside this list, including cannabidiol, is not included in any recommendation - not because it was rejected, but because there was nothing to assess.

Is the endocannabinoid system altered in endometriosis?

Yes, and this is one of the better-documented observations in the field. A study involving 27 women with laparoscopically confirmed diagnosis and 29 women without endometrial pathology measured plasma endocannabinoid levels and receptor expression in endometrial stromal cells (Sanchez, Reproductive Sciences, 2016).

The results are more complex than the simplified version circulating online. Systemic levels of anandamide, 2-arachidonoylglycerol, and oleoylethanolamide were elevated in endometriosis during the secretory phase compared to controls. Simultaneously, CB1 receptor expression in stromal cells was higher in healthy women than patients in the same phase.

The authors interpreted this as possible negative feedback: elevated circulating mediators with reduced local receptor expression may lose pain control ability. They also noted that patients with stronger menstrual and intercourse pain had higher anandamide and palmitoylethanolamide levels, respectively.

An earlier review by the same group described a broader picture. CB1 and CB2 receptors and enzymes for endocannabinoid synthesis and degradation are regulated differently by cycle phase, present in deep endometrial nodules, and in sensory and sympathetic neurons innervating lesions (Sanchez, Molecular Human Reproduction, 2012). Menstrual cycle changes are described in a separate text on the endocannabinoid system in the cycle.

Is endometriosis an endocannabinoid deficiency disease?

Data do not support this. The clinical endocannabinoid deficiency hypothesis was formulated for migraine, fibromyalgia, and irritable bowel syndrome, with evidence from these areas: differences in cerebrospinal anandamide in migraine and imaging indicating reduced system activity in PTSD (Russo, Cannabis and Cannabinoid Research, 2016). Endometriosis is not included.

Moreover, measurements in endometriosis go opposite to this simple hypothesis. Plasma endocannabinoid levels were elevated, not reduced. Peritoneal fluid from 23 patients and 19 controls showed the same: 2-arachidonoylglycerol was higher throughout the cycle in those with non-cyclic abdominal pain (Andrieu, Pain, 2022).

In the same study, 2-arachidonoylglycerol correlated positively with prostaglandin E2, and the anandamide to 2-arachidonoylglycerol ratio correlated with defensins. The authors considered this a possible bridge between the endocannabinoid system and inflammatory pain, noting that causality cannot be determined without further research.

This distinction is important because it determines the reasoning’s validity. The statement “the endocannabinoid system is dysregulated in endometriosis” is supported by measurements. The statement “endocannabinoids are deficient in endometriosis and must be supplemented” is not and is false in light of cited studies.

Where does pain in endometriosis come from?

From at least three overlapping sources, not just lesion presence. First is inflammation around lesions, second their innervation, third nervous system sensitization from years of pain. This is why lesion size seen in imaging does not directly correlate with symptom severity.

Lesion innervation is the most underestimated point. A review on cannabinoid system links to endometriosis indicates CB1 and CB2 receptors and enzymes for endocannabinoid synthesis and degradation are present not only in deep endometrial nodules but also in sensory and sympathetic neurons innervating lesions (Sanchez, Molecular Human Reproduction, 2012). The lesion is not a passive tissue deposit but a structure connected to the nervous system.

Inflammatory components are visible in peritoneal fluid measurements. 2-arachidonoylglycerol correlated positively with prostaglandin E2, a mediator of pain and inflammation, and the anandamide to 2-arachidonoylglycerol ratio correlated with defensins, immune response proteins (Andrieu, Pain, 2022). The authors read this as a possible link between the system and inflammatory pain.

The last component is not local and often overlooked. Pain lasting years changes stimulus processing, and in the Australian survey, people with chronic pelvic pain reported significant negative impacts on social relations, education, and intimate life regardless of diagnosis. Treatment targeting lesions alone does not address this part.

How does cannabidiol act at the molecular level?

More cautiously than usually written. A systematic review of cannabidiol molecular pharmacology identified over 65 described molecular targets but concluded many appear only at supra-physiological concentrations difficult to achieve in the body (Ibeas Bih, Neurotherapeutics, 2015).

The authors’ conclusion is stronger than it seems. They found it very unlikely that cannabidiol acts in neurological diseases via endocannabinoid system modulation. Some targets described show correlation, not causation. After filtering, few remain, linked to intracellular calcium regulation.

This applies to neurological diseases, not endometriosis, which is why it is worth citing. Popular explanations describe cannabidiol action as indirect cannabinoid receptor modulation and inhibition of anandamide-degrading enzyme. The critical review considers this pathway unlikely under physiological conditions.

Cannabidiol is not the same as THC, which acts as a strong CB1 receptor agonist and causes psychoactive effects. In Poland, the threshold for industrial hemp is 0.3%, calculated as the sum of delta-9-THC and tetrahydrocannabinolic acid on a dry weight basis, according to Art. 4 point 5 of the Act of July 29, 2005 on counteracting drug addiction, as amended by the Act of March 24, 2022 (Journal of Laws 2022 item 763).

What did the cannabis survey among women with endometriosis show?

The most cited work on this topic is an Australian online survey published in 2020. It analyzed 484 responses from women aged 18 to 45 with surgically confirmed endometriosis, recruited via social media of patient organizations (Sinclair, Journal of Obstetrics and Gynaecology Canada, 2020).

Numbers are often misquoted, so it is worth stating precisely. Among all respondents, 76% used any self-management methods in the last six months. Among this group, 13% indicated cannabis. So it is not 484 women using cannabis but a clearly smaller subset.

Among cannabis users, self-assessed pain reduction effectiveness was high at 7.6 on a ten-point scale. This is an effectiveness rating, not a measured pain intensity drop. Additionally, 56% reduced medication intake by at least half, with greatest improvement reported in sleep and nausea/vomiting. Adverse effects were rare and mild, reported by 10%.

The authors cautiously conclude that women report good cannabis effectiveness in reducing pain and other symptoms with few adverse effects, but further clinical trials are needed to establish actual effectiveness in endometriosis symptom relief. Even where medical cannabis is more accessible, clinical evidence remains lacking.

What does this survey not say?

Primarily, it says nothing about cannabidiol alone. Questions concerned cannabis as a whole, which also contains THC with a completely different action profile and legal status. Applying such results to a THC-free oil bottle is a substitution of the study subject, not an interpretation.

Secondly, it is a survey without a control group or randomization. Respondents saw announcements in patient organization channels and considered the topic relevant. This selection favors positive responses. Pharmacology cannot be separated from expectations and natural disease fluctuations in such data.

Thirdly, all measures are subjective and retrospective. The “7.6 out of 10” rating is a memory of effectiveness, not a real-time validated measurement. For a disease with variable intensity, such recall is especially unreliable, as authors note.

None of this invalidates patient experience. The survey shows a real phenomenon: women with endometriosis use cannabis and many believe it helps. This is valuable information about the phenomenon’s scale and unmet need. It is not evidence of effectiveness, and the authors do not present it as such.

Is there a clinical trial of cannabidiol in endometriosis?

There is no published randomized placebo-controlled trial testing cannabidiol alone in endometriosis. This is the article’s most important and often omitted sentence. Everything below describes premises, not proof of effectiveness.

A review on endocannabinoids in endometriosis pain treatment describes the system as a significant pharmacological target and discusses pain mechanisms potentially modulated (Bouaziz, Cannabis and Cannabinoid Research, 2017). It is a review suggesting research directions, not a clinical trial report.

Preclinical studies yield ambiguous results. In experimental models, selective cannabinoid receptor agonists limited cell proliferation and alleviated pain symptoms, but endometrial cell migration was rather stimulated by agonists. The 2012 review concluded that mechanisms are just beginning to be understood and further work is needed to assess if the system is a promising target in endometriosis.

What is missing can be precisely listed: randomized placebo-controlled trials with validated endpoints including pain intensity and quality of life, long enough to cover several cycles, and safety data in women on hormonal treatment. Until such a study exists, any “effective dose in endometriosis” is invented.

Do guidelines mention cannabinoids or other non-medical methods?

They do not mention cannabinoids at all. A full-text search of the 2022 guidelines finds no occurrence of words meaning cannabis or cannabinoids, despite 109 recommendations covering pain, infertility, and recurrence management.

This does not mean cannabidiol was rejected. It means there was no material to assess: literature reviews included works published up to December 1, 2020, and no randomized cannabidiol trial in endometriosis existed then or now. The document’s silence is information about evidence status, not a verdict.

Non-medical methods are discussed but assessed cautiously. Authors recommend doctors discuss non-medical strategies supporting quality of life and mental well-being with patients. However, they note no specific method can be recommended due to unclear benefits and harms.

The list under this caveat is long, including Chinese medicine, nutritional interventions, electrotherapy, acupuncture, physiotherapy, physical activity, and psychological interventions (Becker, Human Reproduction Open, 2022). The same statement is repeated separately for infertility, adding no clear evidence that any method increases pregnancy chances. This is worth remembering when reading texts attributing documented effectiveness to anti-inflammatory diets or yoga.

What cannabidiol definitely will not do?

It will not remove endometrial lesions or cure the disease. The World Health Organization states clearly that endometriosis cure is currently unknown, and symptoms can be treated pharmacologically or surgically in some women. No cited study describes anatomical lesion regression due to cannabidiol.

It will not replace gynecologist-led treatment. The 2022 guidelines list pain treatment options as analgesics, pharmacotherapy, and surgery, and for infertility, surgery or assisted reproduction. Cannabidiol is not included in any recommendation, so treating it as a substitute means foregoing the only methods recommended.

It will not solve situations without diagnosis yet. With severe unexplained menstrual pain, the first step is a gynecologist visit, not a supplement. Symptom relief before diagnosis removes the signal guiding medical decisions and adds time to an already long diagnostic path.

There is no basis to consider it an option during pregnancy, breastfeeding, or pregnancy planning. The EFSA panel states cannabidiol safety cannot be established in pregnant and breastfeeding women, those under 25, and those taking medications simultaneously, and a review noted the substance’s ability to cross the placenta (EFSA, 2026).

What risks come from combining cannabidiol with endometriosis treatment?

The main risk is pharmacokinetic and concerns drugs, not the supplement itself. Cannabidiol is metabolized in the liver and can inhibit enzymes and transporters responsible for other substances’ metabolism, altering their blood concentrations. A documented example is clobazam metabolism inhibition (Lucas, British Journal of Clinical Pharmacology, 2018).

For an endometriosis patient, this directly relates because primary treatment is usually hormonal and chronic. This does not mean interaction will definitely occur or be clinically significant. It means the direction and scale of change cannot be predicted without knowledge of the specific drug, which the managing physician has, not the seller or article author.

EFSA’s position is unequivocal here. The panel states human data indicate potential liver damage, especially when cannabidiol is used with other drugs, and animal studies show consistent liver toxicity. This is why safety in people taking medications could not be established.

Separately, perioperative period is important. If surgery is planned, all medications must be disclosed to the anesthesiologist because some anesthetics are metabolized by the same liver pathways. A cannabidiol safety review notes its effects on liver enzymes and drug transporters remain insufficiently studied (Iffland, Cannabis and Cannabinoid Research, 2017).

When does pelvic pain require urgent medical visit, not a supplement?

Always when the clinical picture deviates from previous disease course or appears suddenly. The following situations require doctor contact, not self-treatment. The list does not replace medical assessment and is not exhaustive but covers signs where delay is most costly.

• Sudden, severe abdominal pain with abrupt onset, especially with nausea or fainting.
• Unexplained vaginal bleeding outside menstruation.
• Fever accompanying pelvic pain.
• Suspected pregnancy with severe unilateral pain.
• New symptoms not previously present, e.g., rectal bleeding during menstruation, blood in urine, or pain radiating to one leg.
• Increasing pain despite treatment.

The reason for caution is simple. Endometriosis can involve new locations, and some above presentations have unrelated causes where time matters. A symptom masked by an analgesic remains a symptom, just harder to detect, including by the doctor during the visit.

The same applies to less acute but persistent changes. Increasing pain despite treatment and new-location symptoms warrant re-evaluation, not self-increasing anything. Regular gynecological check-ups remain fundamental as the disease course changes over time.

How to discuss cannabidiol with your gynecologist?

Simply and directly, preparing specifics beforehand. Useful are product name, composition including THC content, batch analysis certificate, planned intake time, and clearly stated goal, e.g., sleep improvement or background pain reduction. Dosage discussion makes sense only with a doctor knowing all medications taken.

Provide a full list of drugs and supplements, including over-the-counter ones. From an interaction perspective, it does not matter if the product was bought in a pharmacy or herbal store. What matters are metabolic pathways and whether they overlap with drugs whose levels must remain stable.

A good tool for this conversation is a symptom diary kept before any decision. Recording pain intensity on a numeric scale, sleep quality, work absences, and analgesic use over several cycles provides a picture no memory can replace. It is also the only way to later assess any change.

If the doctor advises against cannabidiol, ask why, as the reason may be specific to your treatment. Medical caution is not prejudice: without controlled studies and with chronic hormonal pharmacotherapy, responsibility for interaction consequences lies with the treating physician. Experiences of other patients are collected in the text CBD for Endometriosis: Does It Help, and a broader review is in Cannabis for Endometriosis.

Frequently Asked Questions

Does CBD cure endometriosis?

No. The World Health Organization states that a cure for endometriosis is currently unknown, and symptoms are treated pharmacologically or surgically. No study describes the regression of endometrial lesions due to cannabidiol. Diagnosed endometriosis requires management by a gynecologist, not self-supplementation.

Is there a clinical trial of CBD in endometriosis?

There is no published randomized placebo-controlled trial testing cannabidiol alone in this disease. The most frequently cited work is an Australian online survey from 2020 concerning cannabis as a whole, without a control group and with respondents recruited through patient organizations.

What did the Sinclair survey really show?

Among 484 respondents, 76% used any self-management methods for symptoms, and among them, 13% indicated cannabis. The self-assessed effectiveness in pain reduction was 7.6 out of 10, and 56% reduced medication intake by at least half. This is a subjective assessment, not a measurement.

Are endocannabinoids deficient in endometriosis?

Measurements indicate the opposite. In a study of 27 patients and 29 control women, plasma levels of anandamide and 2-arachidonoylglycerol were elevated in endometriosis during the secretory phase, alongside lower CB1 receptor expression in endometrial stromal cells. This is dysregulation, not a simple deficiency.

Is laparoscopy the gold standard for diagnosing endometriosis?

The 2022 guidelines of the European Society of Human Reproduction and Embryology challenge laparoscopy and histopathology as reference diagnostic tests, shifting emphasis to clinical diagnosis and imaging. However, a negative imaging result does not exclude disease if symptoms persist.

Is CBD safe with hormonal contraception or dienogest?

This cannot be generally determined. Cannabidiol inhibits liver enzymes and transporters, potentially altering concentrations of chronically taken drugs. EFSA states that CBD safety cannot be established in people taking medications. The decision is made by the managing gynecologist, who knows the full list of preparations.

How much CBD to take for endometriosis?

This article deliberately does not provide any doses. No clinical trial has established an effective dose for this disease, and EFSA states that safety cannot be established in people taking medications, i.e., typical patients with diagnosed endometriosis. Dosage is determined by the managing physician.

Can CBD be used before diagnosis?

This is the least favorable time. According to WHO, the average time to endometriosis diagnosis is 4 to 12 years, and alleviating menstrual pain may prolong this time by removing the signal prompting a visit. With severe pain of unknown cause, the first step is gynecological diagnostics.

Summary: what is known and unknown

It is known that the endocannabinoid system is altered in endometriosis and these changes relate to pain intensity. This was shown by plasma and peritoneal fluid measurements and receptor expression analyses in tissue. This is a real biological premise justifying research on system modulation.

It is also known what has not been shown. There is no controlled trial testing cannabidiol in endometriosis. The most cited work is a cannabis survey, not cannabidiol, and its authors state clinical effectiveness evidence is lacking. The 2022 guidelines do not list cannabidiol among treatment options.

Finally, the risk is known. In a disease treated chronically with hormones, the problem is not the supplement itself but its effect on drug levels, which must remain predictable. EFSA could not establish cannabidiol safety in people taking medications, describing the situation of most patients with diagnosed endometriosis.

An honest summary is: the research direction is reasonable, evidence of effectiveness is absent, and the decision belongs to the managing physician who knows your treatment. If considering cannabidiol for diagnosed endometriosis, bring product composition and symptom diary to the visit. If not diagnosed yet, start with diagnostics.

This article is informational and educational and does not constitute medical advice. Before starting cannabis or CBD for therapeutic purposes, consult a doctor, especially if taking other medications, pregnant, or breastfeeding.

Author: Michał Waluk · Published: 2026-05-11 · Updated: 2026-08-10